The Conversation to Have Before Starting HRT

Educational only. Not medical advice. This guide helps you have a more informed conversation with a qualified clinician. The decision to start HRT involves individualized risk-benefit assessment that only a clinician with your full medical history can provide.

The quality of your HRT decision depends on the quality of the conversation that precedes it. Most women walk into a consultation knowing they are miserable. The hot flashes, the sleep destruction, the mood they do not recognize. Most walk out with a prescription. What happens between those two moments determines whether you get evidence-based care or a cookie-cutter protocol.

Print this out. Open it on your phone. Bring it to your appointment. A thorough clinician will appreciate that you came prepared. Informed questions lead to better treatment decisions.

Ask: How are you diagnosing perimenopause or menopause in my case? By symptoms and cycle history, or by lab testing? For women over 45 with characteristic symptoms, NAMS says lab testing is not required. If a clinician insists on waiting for a “confirmatory” FSH when you have textbook symptoms, they may be adding delay without adding diagnostic value.

Ask: Could any of my symptoms have a different cause? Every menopause symptom has a differential diagnosis. Fatigue could be thyroid, anemia, or sleep apnea. Mood changes could be depression. Hot flashes have rare non-hormonal causes. A thorough clinician considers alternatives, particularly when symptoms are atypical or do not respond as expected.

Ask: Have we checked thyroid function? Hypothyroidism is common in midlife women and produces symptoms that overlap extensively with menopause. A simple TSH screens for this. It should be part of baseline evaluation.

Ask: Should I be evaluated for sleep apnea? Risk increases after menopause. It causes fatigue, mood changes, cognitive problems, and night sweats. These are the same symptoms that brought you to the appointment. Untreated sleep apnea also increases cardiovascular risk.

Ask: What is my breast cancer risk based on family history, and should we do a formal risk assessment? Tools like the Gail model or Tyrer-Cuzick model quantify individual risk. A clinician who prescribes HRT without asking about your family breast cancer history is skipping a critical step.

Ask: Do I have any risk factors for blood clots? Personal or family VTE history, obesity, smoking, Factor V Leiden, prolonged immobility. These determine whether oral estrogen is appropriate or whether transdermal is preferred.

Ask: What is my cardiovascular risk profile? Blood pressure, lipids, diabetes, smoking history. The timing hypothesis (HRT within 10 years of menopause is more favorable) applies broadly, but individual cardiovascular risk still matters.

Ask: Do I have any contraindications you have identified during intake? If the answer is “no, everything looks fine” after a 5-minute questionnaire, push back. A thorough evaluation takes 20 to 30 minutes minimum. See the Side Effects and Risks guide for what should be screened.

Ask: Which estrogen are you recommending? Estradiol or conjugated equine estrogens? And which delivery route: oral, patch, or gel? The choice affects your risk profile. Transdermal estradiol has the most favorable VTE data. If your clinician is prescribing oral conjugated estrogens without discussing alternatives, ask why.

Ask: Which progestogen are you recommending? Micronized progesterone or a synthetic progestin? Emerging evidence suggests micronized progesterone may carry lower breast cancer risk than MPA. Many menopause specialists preferentially prescribe micronized progesterone. If you are being prescribed MPA, ask what the clinical rationale is.

Ask: Is this an FDA-approved product or a compounded formulation? If compounded, why is an FDA-approved alternative not being offered? Compounded has legitimate uses (allergy to excipients, unavailable doses), but “we always prescribe compounded” is not a clinical rationale.

Ask: Are you prescribing continuous or cyclic dosing, and why? This depends on your menopausal stage. If you are still having periods (perimenopause), cyclic is typically appropriate. If you are well past your last period, continuous is standard. See the dosing guide for details.

Ask: What is the total monthly cost including medication, platform fees, consultations, labs, and shipping? The number on the homepage is not always the number on your credit card. Get the all-in figure before committing.

Ask: What follow-up schedule do you use? Standard of care: clinical follow-up at 8 to 12 weeks after starting, then every 6 to 12 months for stable patients. If a clinic prescribes and disappears, that is not adequate oversight.

Ask: What labs will you order, when, and are they included? Baseline labs (lipids, metabolic panel, thyroid, CBC) and follow-up estradiol levels (particularly for transdermal/topical routes where absorption varies) are standard. Some platforms include labs; others require you to pay out-of-pocket.

Ask: If this does not work as expected, what is the plan? A good clinician has a step-two: dose adjustment, route change, add-on therapy, specialist referral. “Let us know if you have any issues” is not a plan.

If any of these apply to your intake experience, consider getting a second opinion.

• Intake took less than 10 minutes and did not ask about breast cancer family history, VTE risk, or cardiovascular history
• You were prescribed HRT without being asked whether you have a uterus (this determines whether you need a progestogen)
• The clinic only offers compounded products and cannot explain why FDA-approved alternatives are not offered
• “Bioidentical” or “anti-aging” language features more prominently than clinical terminology
• No follow-up appointment is scheduled
• You were offered testosterone, DHEA, and other add-ons at the first visit before your baseline symptoms were even evaluated
• Salivary hormone testing is the primary monitoring tool

If Your Clinician Dismisses You

This happens more than it should. You describe hot flashes, sleep destruction, mood changes, and brain fog. Your clinician says “that is just menopause” or “try lifestyle changes first” or “let us check your labs” (and then uses a single normal FSH to close the conversation).

If this happens, you have three options. Advocate directly: “I understand this may be menopause. I am asking for treatment for menopause. NAMS guidelines support HRT for symptomatic women in the timing window. Can we discuss whether I am a candidate?” This works with clinicians who are uninformed but open.

Request a referral: “Can you refer me to a menopause specialist or a NAMS-certified practitioner?” This works when your current clinician does not have the expertise and is willing to acknowledge that.

Switch providers: if a clinician dismisses your symptoms, refuses to discuss treatment, or tells you HRT is too dangerous without evaluating your individual risk profile, they are not providing current evidence-based care. The NAMS practitioner directory (menopause.org) exists specifically for this situation.

You should not have to convince a clinician to take your symptoms seriously. But the reality of menopause care in 2026 is that many women still do. Going in prepared, with a symptom diary, an understanding of the evidence, and a clear sense of what you are asking for, makes the conversation more productive and helps ensure your concerns are addressed.

Print this or open it on your phone. Check off each item as it is addressed during your consultation.

Diagnosis confirmed: perimenopause or menopause diagnosed based on symptoms, cycle history, and (if indicated) lab work. Contraindications screened: breast cancer history, VTE risk, cardiovascular history, liver disease, migraines, medication interactions all asked about. Specific HRT recommended: which estrogen (estradiol or CEE), which route (oral, patch, gel), and which progestogen (micronized progesterone, norethindrone, or Mirena), with rationale for each choice. Risks discussed: VTE risk by route, breast cancer risk by progestogen type, cardiovascular timing discussed. Specific to YOUR risk profile, not a generic disclaimer. Follow-up scheduled: appointment at 8 to 12 weeks after starting, with labs if appropriate. Total cost confirmed: medication, visits, labs, platform fees. The all-in monthly number. Emergency plan clear: what symptoms require ER, what requires urgent call, what can wait for the next appointment.

If any of these items are not addressed during your intake, ask about them directly. A consultation that covers all seven in 30 to 45 minutes is thorough. A consultation that covers two of seven in 10 minutes is inadequate regardless of how friendly the clinician was.